Phaseline

Targets › DTYMK

DTYMK (Thymidylate kinase): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Neurology; next expected readout Jun 2029.

Catalyzes the phosphorylation of thymidine monophosphate (dTMP) to thymidine diphosphate (dTDP), the immediate precursor for the DNA building block dTTP, with ATP as the preferred phosphoryl donor in the presence of Mg(2+). (UniProt, P23919)

Open in Phaseline: the race on DTYMK, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Kenneth Myers, MDdeoxycytidine and deoxythymidine (dC/dT)
Nucleotide replacement therapy; supplies deoxycytidine and deoxythymidine to restore mitoc
TK2, DTYMKPhase 2Mitochondrial DiseasesJun 2029

Conditions

Mitochondrial Diseases (1)

Modalities

small molecule (1)

Companies

Kenneth Myers, MD (1)

Related targets

TK2 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.